ALXO FY 2023 Earnings — ALX Oncology Holdings Inc. Revenue & Financial Results | Market Cap Arena

ALXOALX Oncology Holdings Inc.

$112M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$170M

Net Income

-$161M

EPS (Diluted)

$-3.74

Cash Flow

Operating Cash Flow

-$130M

Free Cash Flow

-$132M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$243M

Total Liabilities

$53M

Stockholders' Equity

$190M

Cash & Equivalents

$22M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$170M	-$127M	-33.6%
Net Income	-$161M	-$123M	-30.2%